BACKGROUND: Achaete-scute complex-like 1 (ASCL1) is a transcription factor important in the malignant development of medullary thyroid cancer (MTC). Activation of Raf-1 signaling is associated with ASCL1 suppression and growth inhibition. Xanthohumol, a natural compound, has recently been shown to have anticancer properties. We thus hypothesized that xanthohumol would suppress growth by activating Raf-1 signaling, thus altering the malignant phenotype of MTC. METHODS: Human MTC cells were treated with xanthohumol (0-30 micromol/L) for up to 6 days. Proliferation was measured by a methylthiazolyldiphenyl-tetrazolium bromide (MTT) colorimetric assay. Western blot analysis was performed for ASCL1 and markers of Raf-1 pathway activation. RESULTS: Treatment of MTC cells with xanthohumol resulted in a dose dependent inhibition of growth. Additionally, induction of phosphorylated ERK1/2 and a reduction of ASCL1 protein was noted. CONCLUSIONS: Xanthohumol is a potent Raf-1 activator in MTC cells. This compound suppresses MTC growth, alters the malignant phenotype, and warrants further preclinical study. Copyright (c) 2010 Elsevier Inc. All rights reserved.
BACKGROUND:Achaete-scute complex-like 1 (ASCL1) is a transcription factor important in the malignant development of medullary thyroid cancer (MTC). Activation of Raf-1 signaling is associated with ASCL1 suppression and growth inhibition. Xanthohumol, a natural compound, has recently been shown to have anticancer properties. We thus hypothesized that xanthohumol would suppress growth by activating Raf-1 signaling, thus altering the malignant phenotype of MTC. METHODS:Human MTC cells were treated with xanthohumol (0-30 micromol/L) for up to 6 days. Proliferation was measured by a methylthiazolyldiphenyl-tetrazolium bromide (MTT) colorimetric assay. Western blot analysis was performed for ASCL1 and markers of Raf-1 pathway activation. RESULTS: Treatment of MTC cells with xanthohumol resulted in a dose dependent inhibition of growth. Additionally, induction of phosphorylated ERK1/2 and a reduction of ASCL1 protein was noted. CONCLUSIONS:Xanthohumol is a potent Raf-1 activator in MTC cells. This compound suppresses MTC growth, alters the malignant phenotype, and warrants further preclinical study. Copyright (c) 2010 Elsevier Inc. All rights reserved.
Authors: H Chen; A Thiagalingam; H Chopra; M W Borges; J N Feder; B D Nelkin; S B Baylin; D W Ball Journal: Proc Natl Acad Sci U S A Date: 1997-05-13 Impact factor: 11.205
Authors: L Delmulle; A Bellahcène; W Dhooge; F Comhaire; F Roelens; K Huvaere; A Heyerick; V Castronovo; D De Keukeleire Journal: Phytomedicine Date: 2006-05-05 Impact factor: 5.340
Authors: Selvi Kunnimalaiyaan; Jose Trevino; Susan Tsai; T Clark Gamblin; Muthusamy Kunnimalaiyaan Journal: Mol Cancer Ther Date: 2015-04-17 Impact factor: 6.261
Authors: Selvi Kunnimalaiyaan; Kevin M Sokolowski; Mariappan Balamurugan; T Clark Gamblin; Muthusamy Kunnimalaiyaan Journal: PLoS One Date: 2015-05-26 Impact factor: 3.240
Authors: Isabelle E Logan; Cristobal L Miranda; Malcolm B Lowry; Claudia S Maier; Jan F Stevens; Adrian F Gombart Journal: Int J Mol Sci Date: 2019-03-09 Impact factor: 5.923
Authors: Samuel Engelsgjerd; Selvi Kunnimalaiyaan; Emad Kandil; T Clark Gamblin; Muthusamy Kunnimalaiyaan Journal: PLoS One Date: 2019-03-14 Impact factor: 3.240
Authors: Tatjana Seitz; Christina Hackl; Kim Freese; Peter Dietrich; Abdo Mahli; Reinhard Manfred Thasler; Wolfgang Erwin Thasler; Sven Arke Lang; Anja Katrin Bosserhoff; Claus Hellerbrand Journal: Cancers (Basel) Date: 2021-01-29 Impact factor: 6.639